Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
The number of diagnosed prevalent cases of JIA in the countries under study will remain relatively stable over the 20 years of our forecast period. Of the countries considered in this analysis…
Clarivate Epidemiology’s coverage of juvenile idiopathic arthritis (JIA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of nonalcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of fibromyalgia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
The number of total prevalent cases of fibromyalgia in the countries under study will remain relatively stable over the 20 years of our forecast period. Of the countries considered in this…